These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8287064)

  • 21. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
    Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
    Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
    Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
    Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
    Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
    Yokoi T; Kamataki T
    Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.
    Crespi CL; Steimel DT; Penman BW; Korzekwa KR; Fernandez-Salguero P; Buters JT; Gelboin HV; Gonzalez FJ; Idle JR; Daly AK
    Pharmacogenetics; 1995 Aug; 5(4):234-43. PubMed ID: 8528270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese].
    Yokoi T; Kamataki T
    Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
    Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
    J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
    Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
    Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
    Dahl ML; Yue QY; Roh HK; Johansson I; Säwe J; Sjöqvist F; Bertilsson L
    Pharmacogenetics; 1995 Jun; 5(3):159-64. PubMed ID: 7550367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
    Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
    Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
    Tyndale RF; Sunahara R; Inaba T; Kalow W; Gonzalez FJ; Niznik HB
    Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
    Daly AK; Leathart JB; London SJ; Idle JR
    Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.